Clinical trials
catalyst calendar across sponsors →Studies where HROW is the lead sponsor, as filed with ClinicalTrials.gov. Completion dates are the sponsor's own projected windows and are revised as a study runs. Active studies first, then completed and stopped — newest readout first within each.
3 interventional
Held by 8 tracked-famous managers (MARSHALL WACE, LLP, CITADEL ADVISORS LLC, Schonfeld Strategic Advisors LLC, SUSQUEHANNA INTERNATIONAL GROUP, LLP, MILLENNIUM MANAGEMENT LLC, +3 more) · FINRA short interest 11.8 days to cover (settled 2026-07-31) · government filings 180d: none disclosed
| Study | Phase | Status | Interventions | Conditions | Enrollment | Primary completion | Readout in | Updated |
|---|---|---|---|---|---|---|---|---|
| Study Evaluating the Efficacy and Safety of Chloroprocaine HCl Ophthalmic Gel 3% vs Proparacaine Ophthalmic Solution 0.5% Plus Subconjunctival Lidocaine in Patients Undergoing Intravitreal InjectionsNCT07456826Proportion of Participants Achieving Successful Ocular Surface AnesthesiaRandomized · Double-masked · Prevention | Phase 4 | Enrolling by invitation | Drug: Chloroprocaine Ophthalmic Gel 3% (IHEEZO), Proparacaine Hydrochloride Ophthalmic Solution 0.5%, Lidocaine Hydrochloride Injection 2% · Procedure: Sham Subconjunctival Injection | Diabetic Macular Edema (DME), Age-Related Macular Degeneration (AMD), Retinal Vein Occlusion, Diabetic Retinopathy (DR) | 236 | Aug 2026 | ≤ 12 d | 2026-04-07 |
| The Effects of Low Viscosity Chloroprocaine Ophthalmic Gel 3% on the Bactericidal Action of Povidone-IodineNCT05934253Change in colony forming unitsRandomized · Double-masked · Prevention | Phase 4 | Completed | Drug: Chloroprocaine ophthalmic gel 3% | Antiseptic, Anesthesia, Local | 100 | 2024-01-15actual | — | 2025-09-16 |
| Tolerability Comparison of Flarex to Lotemax SMNCT07588074Subject-rated ocular comfortRandomized · Double-masked · Treatment | Phase 4 | Completed | Drug: Fluorometholone Acetate Ophthalmic Suspension 0.1%, Loteprednol Etabonate Ophthalmic Gel 0.38% | Ocular Inflammation, Keratoconjunctivitis, Dry Eye Disease (DED), Post-operative Complications, Kerato Conjunctivitis Sicca, Dry Eye Syndromes, Postoperative Complications | 40 | 2021-06-30actual | — | 2026-05-14 |
Primary completion is the date the sponsor filed with the registry — their own projection, revised whenever they revise it, unless the row is marked actual.
Source: ClinicalTrials.gov, retrieved 2026-08-19